AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9232713 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccinated at their own request and paying the usual fee)
Number of subjects: 585
Study 7955811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin with sucralfate (1 gm)
Number of subjects: 8
Study 7955811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin with ferrous sulfate (100 mg elemental iron)
Number of subjects: 8
Study 7955811 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin with calcium carbonate (500 mg calcium)
Number of subjects: 8
Study 7955811 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin with milk (300 ml)
Number of subjects: 8
Study 7955811 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin alone
Number of subjects: 8
Study 3311119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 0
Study 3311119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and Carbenicillin
Number of subjects: 0
Study 3311119 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 3311119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimen
Number of subjects: 0
Study 31565912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Number of subjects: 8
Study 31565912 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 8
Study 29947919 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIR-Net hospitals
Number of subjects: 475
Study 29947919 — intervention group
Group type: COMPARATOR
Intervention: Non-CHIR-Net hospitals
Number of subjects: 475
Study 28494974 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with defibrillator (CRT-D)
Number of subjects: 1214
Study 28494974 — intervention group
Group type: COMPARATOR
Intervention: ICD alone
Number of subjects: 1214
Study 28494974 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1214
Study 25615445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 0
Study 25615445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22883561 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary split-thickness skin grafting after excision of carbuncle
Number of subjects: 0
Study 20871416 — intervention group
Group type: COMPARATOR
Intervention: Group-C: fortnightly follow-up at community-based follow-up units, including growth monitoring and promotion, health education, and micronutrient supplementation (n = 17)
Number of subjects: 77
Study 20871416 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-SF: same as group-C plus supplementary food (150 to 300 kcal/day) (n = 23)
Number of subjects: 77
Study 20871416 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-PS: same as group-C plus psychosocial stimulation (n = 17)
Number of subjects: 77
Study 20871416 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-SF + PS: same as group-C plus SF and PS (n = 20)
Number of subjects: 77
Study 20871416 — intervention group
Group type: COMPARATOR
Intervention: Nonmalnourished children (comparison group) (n = 17)
Number of subjects: 77
Study 18266048 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P
Number of subjects: 30
Study 18266048 — intervention group
Group type: COMPARATOR
Intervention: Control (no (32)P)
Number of subjects: 30
Study 16901593 — intervention group
Group type: EXPERIMENTAL
Intervention: Invivac (Solvay Pharmaceuticals)
Number of subjects: 0
Study 16901593 — intervention group
Group type: COMPARATOR
Intervention: Fluad (Chiron)
Number of subjects: 0
Study 12749757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 20 mg/day
Number of subjects: 0
Study 12749757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10908933 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 43
Study 10908933 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 43
Study 10908933 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft
Number of subjects: 43
Study 10908933 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 43
Study 9173649 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with internal endometriosis
Number of subjects: 16
Study 9173649 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy women)
Number of subjects: 16
Study 1601605 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with ethyl propionate
Number of subjects: 0
Study 1601605 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with isopropyl acetate
Number of subjects: 0
Study 1601605 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy with 70%:30% MTBE/DMSO mixture
Number of subjects: 0
Study 1601605 — intervention group
Group type: COMPARATOR
Intervention: Bile (control)
Number of subjects: 0
Study 6423063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen treatment
Number of subjects: 0
Study 6423063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30321833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT)
Number of subjects: 54
Study 30321833 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen (SO)
Number of subjects: 54
Study 27049176 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 60
Study 27049176 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no theophylline)
Number of subjects: 60
Study 27049176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 24755136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg before sleep with noise exposure
Number of subjects: 8
Study 24755136 — intervention group
Group type: COMPARATOR
Intervention: Control (Lorazepam 1 mg before sleep without noise exposure)
Number of subjects: 8
Study 22377540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0
Study 22377540 — intervention group
Group type: COMPARATOR
Intervention: Arginine vasopressin
Number of subjects: 0
Study 22377540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20350990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration oxygen (40% and high concentration via Hudson non-rebreathing mask)
Number of subjects: 13
Study 20350990 — intervention group
Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 13
Study 18331216 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (380 mg/day)
Number of subjects: 15
Study 18331216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg/day)
Number of subjects: 15
Study 18331216 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbasalate and placebo (pooled)
Number of subjects: 15
Study 16341372 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg) administered twice a day for 15 days in addition to inhaled salbutamol and ipratropium bromide
Number of subjects: 38
Study 16341372 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice a day for 15 days in addition to inhaled salbutamol and ipratropium bromide
Number of subjects: 38
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen alone
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestrogen combined with progestin
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HRT
Number of subjects: 0
Study 12763518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study 10872714 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape recordings for home use for one week
Number of subjects: 50
Study 10872714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tape recordings)
Number of subjects: 50
Study 8622076 — intervention group
Group type: COMPARATOR
Intervention: CMFVP (Cyclophosphamide, Methotrexate, Fluorouracil, Vincristine, and Prednisone)
Number of subjects: 945
Study 8622076 — intervention group
Group type: EXPERIMENTAL
Intervention: VATH (Vinblastine, Doxorubicin, Thiotepa, and Halotestin)
Number of subjects: 945
Study 8622076 — intervention group
Group type: EXPERIMENTAL
Intervention: VATH
Number of subjects: 945
Study 1289923 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 200 mg/day intramuscularly
Number of subjects: 63
Study 1289923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 6377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostaglandin E2 vaginal gel
Number of subjects: 0
Study 6377145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31245006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose behavioral treatment (24 sessions)
Number of subjects: 287
Study 31245006 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose behavioral treatment (16 sessions)
Number of subjects: 287
Study 31245006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose behavioral treatment (8 sessions)
Number of subjects: 287
Study 31245006 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutrition education, 8 sessions)
Number of subjects: 287
Study 29986700 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing
Number of subjects: 322
Study 29986700 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing
Number of subjects: 322
Study 27473269 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 0
Study 27473269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24657555 — intervention group
Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment based on the SDA concept
Number of subjects: 0
Study 24657555 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment using RPDs
Number of subjects: 0
Study 22980305 — intervention group
Group type: EXPERIMENTAL
Intervention: Edifoligide
Number of subjects: 3014
Study 22980305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3014
Study 19395186 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+AST (radiation plus 6 months of androgen suppression therapy)
Number of subjects: 206
Study 19395186 — intervention group
Group type: COMPARATOR
Intervention: RT (radiation therapy)
Number of subjects: 206
Study 17319791 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline therapy (PA)
Number of subjects: 31
Study 17319791 — intervention group
Group type: EXPERIMENTAL
Intervention: Different antitumor drugs (P0)
Number of subjects: 31
Study 17319791 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 31
Study 17319791 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity (BRS)
Number of subjects: 31
Study 17319791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-beat interval (IBI)
Number of subjects: 31
Study 11004860 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (n=1726)
Number of subjects: 3004
Study 11004860 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (n=1278)
Number of subjects: 3004
Study 9095608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and fentanyl (group E)
Number of subjects: 75
Study 9095608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl and bupivacaine (group I)
Number of subjects: 75
Study 9095608 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (group C)
Number of subjects: 75
Study 9095608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (group I)
Number of subjects: 75
Study 8455424 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (3 million units, three times weekly)
Number of subjects: 48
Study 8455424 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone withdrawal followed by interferon alfa (3 million units, three times weekly)
Number of subjects: 48
Study 8455424 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous normalization without treatment
Number of subjects: 48
Study 8455424 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone pretreatment followed by interferon therapy
Number of subjects: 48
Study 8455424 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone pretreatment followed by interferon therapy
Number of subjects: 48
Study 8455424 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rebound after prednisolone withdrawal
Number of subjects: 48
Study 8455424 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical relapse after therapy
Number of subjects: 48
Study 3094355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 or 40 mg 3 times daily)
Number of subjects: 63
Study 3094355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27995728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiel-embalmed cadavers (T)
Number of subjects: 282
Study 27995728 — intervention group
Group type: COMPARATOR
Intervention: Mannequins only (NT)
Number of subjects: 282
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g) with light load training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen protein supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen protein supplementation (20 g) with light load training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates supplementation (20 g) with heavy progressive resistance training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates supplementation (20 g) with light load training
Number of subjects: 205
Study 27507236 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g)
Number of subjects: 205
Study 25040429 — intervention group
Group type: EXPERIMENTAL
Intervention: HiSCR achievers
Number of subjects: 138
Study 25040429 — intervention group
Group type: EXPERIMENTAL
Intervention: HiSCR
Number of subjects: 138
Study 21883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless PCNL
Number of subjects: 1365
Study 21883839 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 1365
Study 20334979 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CRT
Number of subjects: 3913
Study 20334979 — intervention group
Group type: COMPARATOR
Intervention: Postoperative CRT
Number of subjects: 3913
Study 20334979 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy added to radiotherapy
Number of subjects: 3913
Study 18703940 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (37.5-300 mg/day)
Number of subjects: 0
Study 18703940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15802690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0
Study 15802690 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 0
Study 12877448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 microg used as needed (FP200PRN)
Number of subjects: 241
Study 12877448 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 241
Study 10382190 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 53
Study 8730971 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (200 micrograms)
Number of subjects: 8
Study 8730971 — intervention group
Group type: COMPARATOR
Intervention: Tyramine (75 mM; 2 x 10 microliters)
Number of subjects: 8
Study 8730971 — intervention group
Group type: COMPARATOR
Intervention: Methoxamine (20 mM; 2 x 10 microliters)
Number of subjects: 8
Study 1929293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g, single dose)
Number of subjects: 0
Study 1929293 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg, every 8 h for a total of four doses)
Number of subjects: 0
Study 31401841 — intervention group
Group type: EXPERIMENTAL
Intervention: Zumba intervention (twice-weekly group classes)
Number of subjects: 53
Study 31401841 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintenance of habitual exercise)
Number of subjects: 53
Study 31112475 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by involved-field radiotherapy for PET-positive patients (n = 143)
Number of subjects: 562
Study 31112475 — intervention group
Group type: COMPARATOR
Intervention: Involved-field radiotherapy (n = 208)
Number of subjects: 562
Study 31112475 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (n = 211)
Number of subjects: 562
Study 27650876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed diet plan
Number of subjects: 66
Study 27650876 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-counting diet
Number of subjects: 66
Study 26017129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention with a daily checklist, definition of daily care goals during multidisciplinary daily rounds, and clinician prompts.
Number of subjects: 118
Study 26017129 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 118
Study 23360820 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble αKL preoperatively in acromegaly group
Number of subjects: 14
Study 23360820 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble αKL postoperatively in acromegaly group (early follow-up 2-6 days)
Number of subjects: 14
Study 23360820 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble αKL postoperatively in acromegaly group (late follow-up 2-3 months)
Number of subjects: 14
Study 23360820 — intervention group
Group type: COMPARATOR
Intervention: Soluble αKL preoperatively in control group
Number of subjects: 14
Study 23360820 — intervention group
Group type: COMPARATOR
Intervention: Soluble αKL postoperatively in control group (early and late follow-up)
Number of subjects: 14
Study 21506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavior treatment (MBT) with hand massage
Number of subjects: 83
Study 21506633 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavior treatment (MBT) without hand massage
Number of subjects: 83
Study 21506633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 20799476 — intervention group
Group type: EXPERIMENTAL
Intervention: IVN201 (functional fusion peptide) administered via intralymphatic immunotherapy (ILIT)
Number of subjects: 0
Study 20799476 — intervention group
Group type: EXPERIMENTAL
Intervention: IVN201 (functional fusion peptide)
Number of subjects: 0
Study 20799476 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIT (Intralymphatic immunotherapy)
Number of subjects: 0
Study 20799476 — intervention group
Group type: EXPERIMENTAL
Intervention: MAT molecules (Modular‐Antigen‐Transportation proteins)
Number of subjects: 0
Study 18025996 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard gel
Number of subjects: 55
Study 18025996 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 55
Study 18025996 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital findings
Number of subjects: 55
Study 15992794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological activation during semantic access in reading Chinese characters
Number of subjects: 0
Study 15992794 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop effects from semantically congruent, phonologically congruent, semantically incongruent, phonologically incongruent, and neutral relationships
Number of subjects: 0
Study 15992794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological activation in semantic retrieval
Number of subjects: 0
Study 12043953 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release glipizide GITS (Glucotrol XL) 20 mg once daily
Number of subjects: 0
Study 12043953 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release glipizide (Glucotrol) 10 mg twice daily
Number of subjects: 0
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: European Carotid Surgery Trial measurements
Number of subjects: 20
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid measurements
Number of subjects: 20
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: North American Symptomatic Carotid Endarterectomy Trial measurements
Number of subjects: 20
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Doppler mode after enhancement
Number of subjects: 20
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: Common carotid measurements in power Doppler mode after enhancement
Number of subjects: 20
Study 10082353 — intervention group
Group type: EXPERIMENTAL
Intervention: European Carotid Surgery Trial measurements using nonenhanced power Doppler or color Doppler sonography
Number of subjects: 20
Study 7737631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (25-micrograms bolus)
Number of subjects: 59
Study 7737631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous octreotide (infusion of 50-micrograms/hr)
Number of subjects: 59
Study 2393282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 250 mg
Number of subjects: 12
Study 2393282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg
Number of subjects: 12
Study 2393282 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg
Number of subjects: 12
Study 2393282 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg
Number of subjects: 12